Corrigendum: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: A phase I study using the TITE-CRM model (Annals of Oncology (2015) 26 (1459-1464) DOI: 10.1093/annonc/mdv171);Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: A phase I study using the TITE-CRM model

Annals of Oncology

Volumn 26, Issue 7, 2015, Pages 1459-1464

  Chugh, Rashmi ^a   Griffith, K A ^a   Davis, E J ^a   Thomas, D G ^b   Zavala, J D ^c   Metko, G ^a   Brockstein, B ^d   Undevia, S D ^c   Stadler, W M ^c   Schuetze, S M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

Cardiotoxicity; Cixutumumab; Doxorubicin; IGF 1R; Soft tissue sarcoma; TITE CRM

Indexed keywords

CIXUTUMUMAB; DOXORUBICIN; SOMATOMEDIN C RECEPTOR; ANTI-IGF-1R ANTIBODY A12; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONNECTIVE TISSUE DISEASE; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EYE DISEASE; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; INNER EAR DISEASE; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISEASE; SOFT TISSUE SARCOMA; SURVIVAL TIME; THORAX DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT DISEASE; VASCULAR DISEASE; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; GENETICS; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SARCOMA; STATISTICAL MODEL; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, IGF TYPE 1; SARCOMA; SURVIVAL RATE; YOUNG ADULT;

EID: 84938394069     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy557     Document Type: Erratum

References (22)

1. Ryan CW, Desai J. The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma. Am Soc Clin Oncol Educ Book 2013; 2013: 386-393.
2. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003; 107: 873-877.
3. Bohula EA, Playford MP, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. Anticancer Drugs 2003; 14: 669-682.
4. Zhang H, Yee D. The therapeutic potential of agents targeting the type I insulin-like growth factor receptor. Expert Opin Investig Drugs 2004; 13: 1569-1577.
5. Beech D, Pollock RE, Tsan R et al. Epidermal growth factor receptor and insulinlike growth factor-I receptor expression and function in human soft-tissue sarcoma cells. Int J Oncol 1998; 12: 329-336.
6. Mitsiades CS, Mitsiades NS, McMullan CJ et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5:221-230.
7. Roholl PJ, Skottner A, Prinsen I et al. Expression of insulin-like growth factor 1 in sarcomas. Histopathology 1990; 16: 455-460.
8. Scotlandi K, Maini C, Manara MC et al. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther 2002; 9: 296-307.
9. Schoffski P, Adkins D, Blay JY et al. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer 2013; 49: 3219-3228.
10. Beech DJ, Perer E, Helms J et al. Insulin-like growth factor-I receptor activation blocks doxorubicin cytotoxicity in sarcoma cells. Oncol Rep 2003; 10: 181-184.
11. Luk F, Yu Y, Walsh WR, Yang JL. IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines. Cancer Invest 2011; 29: 521-532.
12. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17:1474-1481.
13. Visscher H, Ross CJ, Rassekh SR et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012; 30:1422-1428.
14. Wojnowski L, Kulle B, Schirmer M et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005; 112: 3754-3762.
15. Borden EC, Amato DA, Rosenbaum C et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987; 5:840-850.
16. Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am 1995; 9: 765-785.
17. Lorigan P, Verweij J, Papai Z et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007; 25:3144-3150.
18. Judson I, Verweij J, Gelderblom H et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic softtissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 2014; 15:415-423.
19. Pappo AS, Patel SR, Crowley J et al. R1507, a monoclonal antibody to the insulinlike growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 2011; 29: 4541-4547.
20. Tap WD, Demetri G, Barnette P et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol 2012; 30: 1849-1856.
21. Troncoso R, Ibarra C, Vicencio JM et al. New insights into IGF-1 signaling in the heart. Trends Endocrinol Metab 2014; 25: 128-137.
22. Ades F, Zardavas D, Pinto AC et al. Cardiotoxicity of systemic agents used in breast cancer. Breast 2014; 23: 317-328.